Intermediate-dose cytarabine is an effective therapy for adults with non-Langerhans cell histiocytosis.

Ting LiuHua-Cong CaiHao CaiMiao ChenWei ZhangJian LiDao-Bin ZhouXin-Xin Cao

Published in: Orphanet journal of rare diseases (2022)

Intermediate-dose cytarabine is an efficient treatment option for non-Langerhans cell histiocytosis patients, especially for those with CNS involvement.

Keyphrases

acute myeloid leukemia
single cell
end stage renal disease
high dose
cell therapy
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
stem cells